Phase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in ulcerative colitis (UC) using FDA-defined endpoints Biomarker analyses showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback